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Despite the extensive literature clearly demonstrating the survival benefit for adjuvant chemotherapy in women with operable breast
cancer, there are few data confirming this in routine practice. Some studies have suggested that not all women gain to the same
extent, with older women showing a smaller benefit and lower doses achieving poorer outcomes. We therefore reviewed the case
notes of 750 women treated over a 15-year period at The Edinburgh Cancer Centre with the same intravenous CMF
(cyclophosphamide, methotrexate and 5-fluorouracil) regimen, to identify patient- and treatment-related factors influencing outcome
in routine practice.The actuarial 10-year survival for these women was 59.3%, with the anticipated poorer outcome for those with
more involved ipsilateral axillary nodes, higher grade and ER-negative tumours. There was no evidence that a lower delivered dose
intensity or older age at presentation resulted in a poorer survival. Of particular interest was the observation that 45% of patients
who had grade 2/3 neutropenia had a 10% absolute survival advantage over those with no neutropenia (Po0.001). This strongly
suggests that some degree of neutropenia has more influence on outcome than age or delivered dose intensity.
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It is clear from the Early Breast Cancer Trialists’ Collaborative
Group overview analyses, and from many of the individual trials
that have contributed to those meta-analyses, that adjuvant
polychemotherapy improves the survival for women with early
breast cancer (Early Breast Cancer Trialists Collaborative Group,
1992, 1998). Much debate has followed as to the optimum duration
and schedule, and several studies have addressed these questions.
At least one prospective study has shown that lower doses of
cyclophosphamide, adriamycin and 5-fluorouracil are associated
with a poorer outcome (Wood et al, 1994). Retrospective analysis
of the pivotal Milan trial with classical CMF (cyclophosphamide,
methotrexate and 5-fluorouracil) noted that those patients who
received less than 85% of the planned dose did not fare as well as
those who did and, more importantly, that those who received less
than 65% of their planned dose had a survival no better than the
untreated patients in the control arm (Bonadonna et al, 1995a). It
was noted in that study that there was a strong tendency for the
older patients to be undertreated, and in a subsequent study from
the same group, looking at alternating CMF and adriamycin, it is
clear that older women had a poorer outcome than younger
women on the same regimen (Bonadonna et al, 1995b). Interest-
ingly, in a recent audit of over 300 patients treated with that same
adriamycin-CMF regimen in 11 centres in UK, Ireland and New
Zealand, there was no difference in outcome for older patients
(Cameron et al, 2002). These data, together with the observation
from the meta-analysis that the benefit of adjuvant chemotherapy
appears to diminish with increasing age, led us to hypothesise that
it may be a failure to deliver drug dose and/or dose intensity in the
older adjuvant breast cancer patient that results in its apparent
reduced efficacy.
In contrast, there are clear retrospective data to suggest that
patients who experience at least some degree of neutropenia while
on their adjuvant chemotherapy may have an improved survival.
The first study to report that neutropenia detected by a routine
nadir full blood count predicted for a better outcome, utilised a
regimen containing an oral fluoropyrimidine and could therefore
be explained on the basis of variable absorption of the oral
medication (Saarto et al, 1997). A more recent study looking at
patients treated with adjuvant CMF regimens in Toronto also
reported similar findings (Mayers et al, 2001).
We therefore additionally hypothesised that patients with
evidence of neutropenia while on a totally intravenous CMF
regimen would have a better survival than similar patients for
whom there was no evidence of myelotoxicity.
MATERIALS AND METHODS
Patients were identified within the departmental database as
having been prescribed to receive six cycles of intravenous CMF
(vide infra for doses) as adjuvant postoperative chemotherapy for
a diagnosis of invasive breast cancer. Patients were to have started
treatment between the years 1984 and 1998. Before 1984 there were
very few patients, and they had been treated with an oral
cyclophosphamide-based regime, the so-called ‘classical CMF’.
The year 1998 was chosen as the cutoff in order to give a minimum
follow-up period of 2 years. We identified 750 patients who met the
criteria. The notes were then examined, and details of the dose and
timing of each cycle of CMF were retrieved, along with any
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lcomments on toxicities, infections and the lowest recorded
neutrophil count for each cycle.
Disease-free and overall survivals are measured from the date of
first chemotherapy (or radiotherapy if that was given first), and are
cause-specific except where stated.
Treatment
All patients had to have been planned to be treated with six cycles
of intravenous CMF on a 21- day cycle. In all, 559 women (75%)
were given the standard regimen at the following doses: cyclopho-
sphamide, 750mgm
 2; methotrexate, 50mgm
 2 and 5-fluorour-
acil, 600mgm
 2.
Of the women (including the majority of the patients over 60
years), 154 (21%) were given only 600mgm
 2 of cyclopho-
sphamide. The remaining 37 patients had either some other
planned dose or the planned dosagem
 2 was not clearly defined
(although the actual doses were). All other treatments received
(surgical, radiotherapeutic and hormonal) were noted, but did not
form a basis for including or excluding patients from the audit.
Dose intensity
The usual policy for radiotherapy throughout this period was to
administer it between either the first and second cycles in the
earlier years, or between the third and fourth cycles of
chemotherapy. Thus, patients scheduled for radiotherapy would
automatically have a lower received dose intensity by virtue of this
planned gap in chemotherapy administration. Therefore, analyses
of dose intensity were made with and without an allowance for this
gap. Since the standard cycle interval was 21 days, and there can be
no delay after the final cycle, dose intensity was calculated for all
patients receiving six cycles as
doseintensity ¼
totaldose
totalintendeddose
 
5 21
ðtimeðindaysÞbetweenfirstandlastdoses
Neutropenia
The grade of neutropenia was based on the lowest recorded
neutrophil count for a patient between the day of first
chemotherapy and 3 weeks after the final dose administered. The
grading system used was that of the NCIC (so that grade 2 equates
to a neutrophil count of between 1.0 and 1.5 10
9 cellsl
 1 and
grade 3 equates to a count of between 0.5 and 1 10
9 cellsl
 1).
Statistics
All statistical analyses and survival curves were produced using
SAS Proprietary software (Copyright 1999–2001, SAS Institute,
Cary, NC, USA). Survival data (including Figure 1) are breast
cancer specific unless otherwise stated. Proportional hazards
analysis was performed for all patients who completed six courses
of CMF chemotherapy. All patient-related, pathological and
treatment-related variables were entered into the model and the
analysis was performed by backward elimination.
RESULTS
Demographics and tumour details (see Table 1)
The majority of patients (83%) were treated after 1993, and were
most commonly premenopausal (70%), stage II disease (70%),
grade 3 cancers (67%) and/or with pathologically involved lymph
nodes (68%). In all, 80% tumours were classified as ductal/no
special type. ER status was known to be positive (419fmolmg
 1
or histoscore 480) in 46%, poor (detectable but below the criteria
for positive) in 23%, completely negative in 23% and unknown in
8%.
The median age overall was 47.9 (range 24–76) years, but
increased significantly over time so that it was 43 years for patients
treated between 1984 and 1992, 46 years for those treated between
1993 and 1995, and 50 years between 1996 and 1998.
Treatment details
These have been summarised in Table 2. Of note is that for the 606
patients who received radiotherapy, it was intercalated in 84%,
given before chemotherapy in 7% and given after chemotherapy in
the remaining 9%. The majority (56%) had their radiotherapy
between the third and fourth courses of chemotherapy.
Adjuvant hormonal therapy was known to have been given to
47% of patients. In 42% of patients tamoxifen was given, and 5%
had ovarian ablative therapy (7tamoxifen). The vast majority of
patients given endocrine therapy had some degree of ER
expression, with only 24 patients being given tamoxifen for ER
totally negative tumours. Among patients with ER-poor tumours,
37% were known to have received endocrine therapy, and 83% of
those with ER-positive/rich tumours received further hormonal
therapy.
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Figure 1 Breast-cancer-specific overall survival for all 750 patients
treated with three-weekly i.v. CMF.
Table 1 Summary of patient and tumour characteristics by year of
treatment
1984–1992 1993–1995 1996–1998 Total
Number of patients 131 216 403 750
Median age (years) 43 46 50 47.9
Pathological size (mean) 26.5 22.3 22.5 23.1
% T 1 2 83 23 9 3 5
% T 2 6 46 05 5 5 8
% node negative 18 23 41 32
% 1–3 node positive 54 60 49 53
% 4–9 node positive 23 14 8 12
% grade 3 84 56 70 67
% ER positive/rich 35 56 51 50
% post menopausal 16 23 38 30
% over 60 years 3 7 17 12
% over 70 years 0 2 2 2
% mastectomy 33 44 40 40
5-year survival (%) 65.4 74.4 74.1 71.5
ER, Oestrogen receptor; XRT, Radiotherapy.
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A total of 53 (7%) patients failed to complete six cycles of
chemotherapy. This was significantly more common in older
women, with 8% of women aged 60–69 years and 21% of women
over 70 years failing to complete their planned therapy (w
2 for
trend¼5.7, Po0.02).
Treatment delays were surprisingly common. Overall, we noted
that 76.6% of patients and 37.5 % of courses had a delay of at least
1 day. Delays for reasons of toxicity occurred in 54% of patients,
with a delay of at least a week occurring in 44% of patients. There
was however no evidence that delays were more common in older
patients.
Documented toxicity
Grade 4 neutropenia (neutrophils o0.5 10
9l
 1) was documented
in 76 (10%) patients, including two of 14 of those over 70 years ,
and 101 of 4255 (2%) of courses. There is an apparent trend for a
lower incidence of neutropenia in later courses, with, for example,
4% following the first course, 3% after the fourth and only 1% in
the final course (w
2 for trend across all six cycles¼16, Po0.001).
It is clear however that in the absence of toxicity, very few
patients had a routine full blood count after cycle 6. Therefore, the
data from that final cycle could be an underestimate, but this
would not in any case have altered treatment delivery. Of the 76
patients with at least one documented neutrophil count below
0.5 10
9l
 1, all but two completed all six cycles (neither of whom
was over 70 years old), one of whom had three episodes of grade 4
neutropenia before the final cycle was omitted. All but two
patients, however, had either a dose reduction (47%) or a
treatment delay.
A highest recorded grade of neutropenia of 2 or 3 was
documented in 133 (17%) and 208 (28%) patients and 5% and
7% of courses, respectively. Patients with grade 2/3 neutropenia
were significantly younger (mean age 48 years) than those with
grade 4 neutropenia (mean age 52 years, Po0.002), and overall
there was a significant trend for higher grades of neutropenia in
older patients (w
2 for trend¼6.87, Po0.01).
Patient outcome
Three patients were lost to follow-up in the first 2 years, leaving a
median follow-up of 4 years for the remaining patients. In all, 17
patients died a nonbreast cancer death, including two that were
probably treatment related (one at home midcycle, and the other
following presumed neutropenic sepsis). A total of 260 patients
have documented relapse of breast cancer, of whom 202 have died
of breast cancer. Actuarial all-cause overall survival was 73.2, 59.3
and 50.3 % at 5, 10 and 15 years, respectively. Breast-cancer-
specific survival rates were 74.6, 62.2 and 52.7%, respectively (see
Figure 1). The strongest predictor of overall survival was the
number of involved axillary lymph nodes, Po0.0001 (see Figure 2).
As might be expected, ER-rich tumours were associated with the
best overall survival of 81% at 5 years as compared with 64% for
ER-poor and 70% for ER-negative tumours.
There was no evidence of any difference in survival between
the three cohorts (see Table 1). The 5-year survival by age is
shown in Table 2, where it can be seen that women aged between
40 and 49 years had the best survival (P¼0.0019). Women over
60 years may appear to have a poorer survival than those
aged between 40 and 59 years, but it is also apparent from Table 2
that they have a higher proportion of tumours with poorer
prognostic factors, for example, within the four categories of
nodal involvement (negative, 1–3, 4–9 and 10þ); there is no
evidence of a poorer disease-free survival for any particular age
group.
Figure 3 shows that the small number of patients (23) who
failed to receive more than three courses had a significantly
poorer survival (P¼0.009). However, there was no evidence that
lower received dose intensities, in the 687 patients completing
all six courses, were associated with any differences in survival
(see Figure 4). There was no evidence that the actual timing
of the radiotherapy had any effect on outcome (data not
Table 2 Summary of patient, tumour and treatment characteristics by
age (years) of patient
o40 40–49 50–59 60–69 70+
Number of patients 149 304 194 89 14
Pathological size (mean)
(mm)
23.0 23.6 21.6 24.4 29.2
% T 1 3 33 24 13 82 9
% T 2 6 15 95 45 56 4
% node negative 45 30 30 24 14
% 1–3 node positive 48 52 58 53 43
% 4–9 node positive 6 15 11 15 21
% grade 3 75 65 61 71 85
% ER positive/rich 38 54 55 43 50
% given tamoxifen 40 45 58 68 83
% post menopausal 3 6 51 100 100
% mastectomy 36 40 41 44 50
% mastectomy patients
given radiation therapy
53 61 46 69 71
% completed six courses 93 93 94 92 79
% achieving 85% dose
intensity
23 21 23 11 9
5-year survival (%) 65.5 78.9 78.9 70 68.3
ER, Oestrogen receptor; XRT, Radiotherapy.
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Figure 2 Breast-cancer-specific overall survival by number of involved
axillary nodes (Po0.0001).
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Figure 3 Breast-cancer-specific overall survival by number of courses of
CMF administered (P¼0.009).
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patients, respectively, received radiotherapy before and after all
their chemotherapy (with 5-year survivals of 69 and 71%,
respectively).
Figure 5 shows the perhaps surprising result that there is an
absolute improvement in overall survival of over 10% for those
women whose maximum recorded level of neutropenia was
grade 2 or 3, as compared with those women who experienced
grades 0, 1 or 4 neutropenia. This difference is seen across all
patient and tumour categories, although in some of the smaller
groups (the earliest cohort, grade 1 and 2 tumours, and ER-rich
tumours) the observed difference is not statistically significant (see
Table 3). Furthermore, if the comparison is made between, on the
one hand, those patients with grade 0 or 1 neutropenia, and on the
other hand those experiencing grade 2 or higher, the latter
continue to have a statistically significant better survival
(P¼0.001), also seen in every subgroup (although no longer
reaching significance in women with ER-poor tumours) (data not
shown).
In multivariate analysis, the degree of neutropenia remains an
independent predictor of a poorer outcome along with the number
of involved axillary nodes, a low ER of the tumour, and the patient
having had a mastectomy (see Table 4). It is also clear that having a
mastectomy is an indicator of poorer outcome, probably because
of its relationship with larger tumour size: there was a mean
pathological size of 27.6mm as compared to the statistically
significantly smaller mean of 20.2mm for the women having breast
conservation (Po0.0001).
DISCUSSION
This retrospective analysis was carried out in order to see if older
women fared worse with adjuvant intravenous CMF as a
consequence of more toxicity and/or lower doses and dose
intensity. Clinicians at our institute had often reduced the dose
of cyclophosphamide, as commented on previously, in anticipation
of higher toxicity in older women. The data presented here,
however, suggest that despite a moderate increase in toxicity, there
is no evidence of a lower dose intensity and poorer outcome for
older women
What is very clear, however, is that in our study, those women,
irrespective of their age, who had moderate neutropenia had a
substantially better survival, with a similar level of gain being seen
within each prognostic group (see Table 3). In two small groups
(the first cohort and those with grade 1 and 2 tumours), the
difference is not statistically significant, and in women with ER-
positive tumours, any difference observed is similarly not
statistically significant. However, similar trends are also seen for
disease-free survival, and in no subgroup is the outcome for
women without neutropenia better than for those with a moderate
degree. Thus even though some observed differences do not reach
statistical significance, they remain consistent with the observation
that modest neutropenia accords a survival advantage in the
adjuvant use of CMF. It is not entirely clear as to why the 10% of
patients who experienced the most severe neutropenia had a
similar outcome to those women who had no neutropenia, but one
important difference may be that they were on average older.
However, as commented on above, the improved survival persists
if they are included in the moderate neutropenia group. Thus,
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Figure 4 Breast-cancer-specific overall survival by average dose intensity
for patients completing six courses of CMF chemotherapy (P¼NS).
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Figure 5 Breast-cancer-specific overall survival by maximum recorded
grade of neutropenia (Po0.001 for grade 2 and 3 combined vs grades 0, 1,
and 4 combined).
Table 3 Details of survival for patients with grade 2/3 neutropenia
5-year cause-specific
survival Grades 0, 1, and 4 Grades 2 or 3 P-value
Number of patients 397 353
Overall 68% 82% o0.0001
1984–1992 64% 71% NS
1993–1995 66% 82% 0.04
1996–1998 72% 86% 0.0027
Age o50 years 72% 82% 0.017
Age 450 years 61% 81% 0.0006
ER negative 59% 83% 0.0008
ER poor 58% 75% 0.008
ER rich 79% 85% NS
Grades 1 and 2 79% 91% NS
Grade 3 66% 76% 0.011
NS, nonsignificant; ER, Oestrogen receptor; XRT, Radiotherapy.
Table 4 Multivariate analysis for relapse-free and cause-specific overall
survival at 5 years
Variable Overall survival
Number of lymph nodes Po0.0001
Grade 2 or 3 neutropenia P¼0.0377
ER poor/negative Po0.0001
XRT to supraclavicular fossa P¼0.0169
Mastectomy P¼0.004
XRT to primary site P¼0.041
Proportional-hazard analysis was performed for all patients who completed six
courses of CMF chemotherapy. All patient-related, pathological and treatment-
related variables, including pathological tumour size, were entered into the model and
the analysis was performed by backward elimination. Only 497 patients were
included in the analysis, due to incomplete information on some variables; in
particular, grade was not available for 136 patients and ER status for 60 patients.
Those variables having a significant effect on cause-specific survival are shown in the
table; ER, Oestrogen receptor; XRT, Radiotherapy.
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neutropenia suggests underdosing, and similar findings have been
reported by others.
Comparable data for a CMF-based regimen come from Canada,
where even in a multivariate analysis, experiencing grade 3 or 4
neutropenia correlated with better survival (Mayers et al, 2001), in
a similar manner to the advantage seen in this study for those
women experiencing grade 2 or 3 neutropenia. Three other factors
were also associated in univariate analyses with an improved
outcome, namely inclusion in a clinical trial, delivery of a dose
intensity above the median and/or the use of the classical CMF
regimen. However, the magnitude of the benefit associated with
these factors was considerably smaller than that seen in women
experiencing neutropenia, and none of these factors were
significant in the multivariate analysis. In another, smaller study
analysing the outcome of 211 women with early breast cancer
administered an adjuvant regimen consisting of bolus doxorubicin
and cyclophosphamide and an oral analogue of %-FU (ftorafur),
Saarto et al (1997) reported a significant correlation between
leucocyte nadir and both disease-free and overall survival. They
also reported that any relationship between the dose intensity of
doxorubicin and cyclophosphamide and outcome was only
significant when patients stopped chemotherapy early, whereas
that with the nadir leucocyte count persisted in a multivariate
analysis.
One criticism of this study relates to the use of a three-weekly
i.v. CMF regimen. We are in the process of comparing these data
with data from another UK unit with 20 years’ experience of using
the ‘classical’ or Bonadonna CMF, but the results are not yet
available. It is interesting, however, to note how the outcome for
the women in our study compares very favourably with that
recently reported by the IBCSG and GBSG, in their combined
analysis of three and six cycles of adjuvant ‘classical’ CMF
(Colleoni et al, 2002), with almost identical 5- and 10-year
survivals. There are of course differences in demographics and risk
factors (patients in our study were on average older, less likely to
have four positive node tumours, but equally less likely to have
ER-positive tumours).
Thus our data, as well as two other retrospective studies (Saarto
et al, 1997; Mayers et al, 2001), strongly suggest that it is the
achievement of neutropenia that could be fundamental to
delivering optimal adjuvant chemotherapy.
However, this is not a justification for high-dose chemotherapy,
for which preliminary data from a number of adjuvant studies
have failed to show any clear advantage for increasing the dose of
adjuvant chemotherapy above which is tolerable without growth
factor or bone marrow stem cell support. In contrast, a small
number of other studies have shown that a planned reduction in
dose is detrimental, such as the CALGB study (Wood et al, 1994),
retrospective analyses from the Institute of Cancer in Milan
(Bonadonna et al, 1995a) as well as a study randomising patients to
different doses of epirubicin (Piccart et al, 2001).
How can we reconcile these data? It is clear from the small study
from Newcastle, UK, looking at the variable pharmacokinetics
of adjuvant CMF in breast cancer, that there is significant
interpatient variability (Batey et al, 2002). We suggest that the
current trend for prescribing chemotherapy using an estimated
body surface area is insufficiently precise to ensure that all patients
receive a sufficient dose, and that our data support a pharmaco-
dynamic definition of adequacy being that which induces modest
neutropenia. If there was a simple way in which this could be
ensured for every patient, then our data, as well as those of others,
would suggest that there would be an overall improvement in
survival, possibly as large as that sought but not yet found, in
studies of myeloablative chemotherapy. Support for this hypoth-
esis was apparent in a study recently reported by the Swedish
group. In their randomised trial, they demonstrated that high-dose
chemotherapy appeared to be inferior to an anthracycline-based
regime with dose escalation according to toxicity (Bergh et al,
2000).
Although it remains a conundrum as to why the plateau of
dose–response in adjuvant chemotherapy appears around the
dose that individually delivers modest neutropenia, the data we
and others report strongly call for studies to test the hypothesis
that adjuvant chemotherapy in early breast cancer has to cause
myelosuppression to be optimal.
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